Elevated Fibroblast Growth Factor 23 Concentration: Prediction of Mortality among Chronic Kidney Disease Patients | Zendy

Shahanas Chathoth | Zendy; Samir Al-Mueilo | Zendy; Cyril Cyrus | Zendy; Chittibabu Vatte | Zendy; Awatif Al-Nafaie | Zendy; Rudaynah A. Alali | Zendy; Brendan J. Keating | Zendy; Fahad AlMuhanna | Zendy; Amein Al Ali | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Elevated Fibroblast Growth Factor 23 Concentration: Prediction of Mortality among Chronic Kidney Disease Patients

Author(s) -

Shahanas Chathoth,

Samir Al-Mueilo,

Cyril Cyrus,

Chittibabu Vatte,

Awatif Al-Nafaie,

Rudaynah A. Alali,

Brendan J. Keating,

Fahad AlMuhanna,

Amein Al Ali

Publication year - 2015

Publication title -

cardiorenal medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.661

H-Index - 21

eISSN - 1664-3828

pISSN - 1664-5502

DOI - 10.1159/000440984

Subject(s) - fibroblast growth factor 23 , medicine , kidney disease , hyperphosphatemia , endocrinology , parathyroid hormone , population , renal function , pathogenesis , biomarker , klotho , renal osteodystrophy , dialysis , cohort , kidney , calcium , biology , biochemistry , environmental health

The osteocyte-derived hormone, fibroblast growth factor 23 (FGF23), regulates the phosphorus metabolism and suppresses 1,25-dihydroxyvitamin D production, thereby mitigating hyperphosphatemia in patients with renal disorders. An elevated FGF23 level is suggested to be an early biomarker of altered phosphorus metabolism in the initial stages of chronic kidney disease (CKD) and acts as a strong predictor of mortality in dialysis patients. In the Saudi population, there is no report on the FGF23 level in CKD patients to date. This study aims to estimate the plasma FGF23 levels in the Saudi population and to correlate it with its clinical manifestations in order to ascertain its role in the pathogenesis of CKD patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research